CLINICAL UTILITY OF A NEUROBLASTOMA MONOCLONAL ANTIBODY

在这项研究中，一种新开发的单抗--单抗126， 对神经节苷脂抗原GD2的反应将是神经母细胞瘤 研究其在诊断和管理方面的潜在应用 神经母细胞瘤。初步研究表明，GD2的表达 抗原似乎仅限于中性粒细胞肿瘤和组织 血清GD2水平可作为两种血清学疾病的肿瘤标志物 神经母细胞瘤的诊断和治疗监测。我们计划进行 一项对患者资料的前瞻性、长期研究，收集自 儿科肿瘤学小组的30多个成员机构。我们会 用单抗126检测组织中GD2抗原的价值 神经母细胞瘤的诊断及临床分期。我们 将检验神经母细胞瘤血清学诊断的有效性，并将 诊断时血清GD2水平与 神经母细胞瘤患者的临床特点及最终转归 它们的预后价值。血清GD2水平将与 评估循环GD2作为肿瘤的有用性的临床过程 监测神经母细胞瘤患者的标志物。我们将搜索 抗GD2循环抗体及其抗原抗体的存在 神经母细胞瘤患者的复合体及其临床意义 关联性。我们还计划检查单抗126和抗体的作用 抗GD2抗体对培养神经母细胞瘤生长的影响 细胞及其GD2抗原的表达。这些承诺将 单抗126在组织诊断和血清学中的应用价值 诊断、临床分期、预测和治疗 神经母细胞瘤的监测。它还可能提供第一个模型系统在 一种定义明确的肿瘤相关抗原与 它的抗体可以被解剖。(2)

In this research, a recently developed monoclonal antibody, Mab 126, reactive with a ganglioside antigen, GD2, on neuroblastoma will be investigated for its potential application to the diagnosis and management of neuroblastoma. Preliminary findings showed that the expression of GD2 antigen appears to be restricted to neurectodermal tumors and tissues and that serum levels of GD2 may serve as a tumor marker for both serological diagnosis and therapeutic monitoring of neuroblastoma. We plan to conduct a prospective, long-term study of patient materials collected from more than 30 member institutions of the Pediatric Oncology Group. We will assess the value of GD2 antigen as detected by Mab 126 in the tissue diagnosis of neuroblastoma and in clinical staging of neuroblastoma. We will test the validity of a serological diagnosis of neuroblastoma and will correlate the serum levels of GD2 at the time of diagnosis with the clinical features and final outcome of neuroblastoma patients to determine their prognostic value. The serum levels of GD2 will be correlated with clinical course to assess the usefulness of circulating GD2 as a tumor marker in monitoring neuroblastoma patients. We will search for the presence of circulating antibody to GD2 and their antigen-antibody complexes in patients with neuroblastoma and determine their clinical relevance. We also plan to examine the effects of Mab 126 and antibody against GD2 found in patients' sera on the growth of culture neuroblastoma cells and their expression of GD2 antigen. These undertakings will delineate the value of Mab 126 in the tissue diagnosis and serological diagnosis, in clinical staging and prognostication, and in therapeutic monitoring of neuroblastoma. It may also provide the first model system in which the interaction between a well-defined tumor-associated antigen and its antibody can be dissected. (2)